Literature DB >> 30773067

Recent advances in the metabolomic study of bladder cancer.

Chandra Sekhar Amara1, Venkatrao Vantaku1, Yair Lotan2, Nagireddy Putluri1,3.   

Abstract

INTRODUCTION: Metabolomics is a chemical process, involving the characterization of metabolites and cellular metabolism. Recent studies indicate that numerous metabolic pathways are altered in bladder cancer (BLCA), providing potential targets for improved detection and possible therapeutic intervention. We review recent advances in metabolomics related to BLCA and identify various metabolites that may serve as potential biomarkers for BLCA. Areas covered: In this review, we describe the latest advances in defining the BLCA metabolome and discuss the possible clinical utility of metabolic alterations in BLCA tissues, serum, and urine. In addition, we focus on the metabolic alterations associated with tobacco smoke and racial disparity in BLCA. Expert commentary: Metabolomics is a powerful tool which can shed new light on BLCA development and behavior. Key metabolites may serve as possible markers of BLCA. However, prospective validation will be needed to incorporate these markers into clinical care.

Entities:  

Keywords:  BLCA; LC-MS; metabolomics

Mesh:

Substances:

Year:  2019        PMID: 30773067      PMCID: PMC6538267          DOI: 10.1080/14789450.2019.1583105

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  100 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Comparison between smoking-related DNA adduct analysis in induced sputum and peripheral blood lymphocytes.

Authors:  A Besaratinia; A Besarati Nia; L M Maas; E M Brouwer; J C Kleinjans; F J Van Schooten
Journal:  Carcinogenesis       Date:  2000-07       Impact factor: 4.944

3.  A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke.

Authors:  Anthony J Alberg; Anthony Kouzis; Jeanine M Genkinger; Lisa Gallicchio; Alyce E Burke; Sandra C Hoffman; Marie Diener-West; Kathy J Helzlsouer; George W Comstock
Journal:  Am J Epidemiol       Date:  2007-01-04       Impact factor: 4.897

4.  Ethnic and racial differences in the smoking-related risk of lung cancer.

Authors:  Christopher A Haiman; Daniel O Stram; Lynne R Wilkens; Malcolm C Pike; Laurence N Kolonel; Brian E Henderson; Loïc Le Marchand
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

5.  Racial disparity in bladder cancer: trends in tumor presentation at diagnosis.

Authors:  Cheryl T Lee; Rodney L Dunn; Candice Williams; Willie Underwood
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

Review 6.  Urine markers for bladder cancer surveillance: a systematic review.

Authors:  Bas W G van Rhijn; Henk G van der Poel; Theo H van der Kwast
Journal:  Eur Urol       Date:  2005-03-23       Impact factor: 20.096

Review 7.  Bulky DNA adducts and risk of cancer: a meta-analysis.

Authors:  Fabrizio Veglia; Giuseppe Matullo; Paolo Vineis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-02       Impact factor: 4.254

8.  Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Authors:  Yair Lotan; Robert S Svatek; Arthur I Sagalowsky
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

9.  N-acetyltransferase 2 phenotype in painters with bladder cancer and controls.

Authors:  K Golka; W Weistenhofer; P Jedrusik; F Geller; M Blaszkewicz; H M Bolt
Journal:  Ann Acad Med Singapore       Date:  2001-09       Impact factor: 2.473

Review 10.  Phospholipase A2 as targets for anti-cancer drugs.

Authors:  Brian S Cummings
Journal:  Biochem Pharmacol       Date:  2007-04-27       Impact factor: 5.858

View more
  7 in total

1.  Data Processing and Analysis in Liquid Chromatography-Mass Spectrometry-Based Targeted Metabolomics.

Authors:  Masahiro Sugimoto; Yumi Aizawa; Atsumi Tomita
Journal:  Methods Mol Biol       Date:  2023

2.  A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients.

Authors:  Oiana Telleria; Oihane E Alboniga; Marc Clos-Garcia; Beatriz Nafría-Jimenez; Joaquin Cubiella; Luis Bujanda; Juan Manuel Falcón-Pérez
Journal:  Metabolites       Date:  2022-06-15

Review 3.  Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.

Authors:  Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

4.  UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.

Authors:  Zhan Wang; Xiaoyan Liu; Xiang Liu; Haidan Sun; Zhengguang Guo; Guoyang Zheng; Yushi Zhang; Wei Sun
Journal:  BMC Cancer       Date:  2019-12-05       Impact factor: 4.430

5.  A Novel Prognostic Signature Based on Ferroptosis-Related Genes Predicts the Prognosis of Patients With Advanced Bladder Urothelial Carcinoma.

Authors:  Xiaoqi Li; Junting Huang; Ji Chen; Yating Zhan; Rongrong Zhang; Enze Lu; Chunxue Li; Yuxiao Zhang; Yajing Wang; Yeping Li; Jianjian Zheng; Wujun Geng
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

6.  Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy.

Authors:  Hongyang Qian; Yiqiu Wang; Zehua Ma; Lei Qian; Xiaoguang Shao; Di Jin; Ming Cao; Shupeng Liu; Haige Chen; Jiahua Pan; Wei Xue
Journal:  Int J Nanomedicine       Date:  2022-04-05

7.  Pre- and Post-Resection Urine Metabolic Profiles of Bladder Cancer Patients: Results of Preliminary Studies on Time Series Metabolomics Analysis.

Authors:  Julia Jacyna; Marta Kordalewska; Małgorzata Artymowicz; Marcin Markuszewski; Marcin Matuszewski; Michał J Markuszewski
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.